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Expression of the Natural Killer cell receptor CD161 has recently been identiﬁed on a sub-
set ofT cells, including both CD4+T helper and CD8+T cells. Expression of this molecule
within the adult circulation is restricted to thoseT cellswith amemory phenotype. However,
the distinct properties of these T cell populations is yet to be fully determined, although
expression of CD161 has been related to the secretion of interleukin-17, and therefore to a
type 17 phenotype. Recent studies have aimed to determine both the origin of these cells
and the signiﬁcance of CD161 expression as either a marker of speciﬁc cell types or as an
effector and regulator of lymphocyte function, and hence to characterize the role of these
CD161 cells within a variety of human diseases in which they have been implicated.+
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INTRODUCTION
The study of immunology is largely based on the division of leuko-
cytes into families, lineages, and subsets; from division between
innate and adaptive immunity, to categorization based on surface
molecule expression and cytokine secretion.Many of those surface
molecules involved in identiﬁcation of subtype also reﬂect effec-
tor function. However, as further cells are identiﬁed these divisions
become less distinct, with some cells demonstrating features from
one or more of the previously deﬁned subsets. As these mole-
cules are often involved in effector function, common expression
of molecules between lineages may suggest overlapping functions.
One set of divisions which are becoming increasingly “blurred”
are those between T lymphocytes, Natural Killer (NK) cells, and
NK-T cells. These subsets share common expression of speciﬁc
molecules, including the C-type lectin CD161. This surface mole-
culewas originally identiﬁed as the humanhomolog of theNKRP1
glycoproteins expressed on rodent NK cells, demonstrating 46–
47% homology with its rodent counterparts. Human NKRP1A, or
CD161, is composed of a disulﬁde-linked homodimer of∼40 kDa
subunits. It is expressed by the majority of NK cells and approx-
imately 24% of peripheral T cells (Lanier et al., 1994), including
both γδ and αβ TCR-expressing subsets (Maggi et al., 2010) and
NK-T cells. As NK-T cells compose less than 1% of human periph-
eral blood T cells (Gumperz et al., 2002), the remainingCD161+T
cells must represent a distinct lineage of T lymphocytes (Takahashi
et al., 2006).
However, the implication of CD161 expression by these T cells
remains to be fully determined – is CD161 simply a phenotypic
marker; identifying T cells of a common activation state and/or
lineage? Or does this C-type lectin perform some signiﬁcant effec-
tor function itself? This review aims to explore recent advances in
the characterization of CD161-expressing T cells, concentrating
particularly on human αβ-TCR T cells, and through this to evalu-
ate the importance of expression to immune function and hence
to human disease.
CD161 AS A PHENOTYPIC MARKER OF T CELLS
CD161 expression is not unique to any predeﬁned T cell sub-
set. Lanier et al. (1994) originally identiﬁed expression on both
CD4+ and CD8+ T cells, with a higher surface density on the lat-
ter. More recently, CD161 expression has also been demonstrated
on CD4−CD8− double negative (DN) TCRαβ+ and TCRγδ+
T cells (Maggi et al., 2010). Further analysis has identiﬁed two
CD161+CD8+ populations (Takahashi et al., 2006; Billerbeck
et al., 2010), with intermediate or high CD161 expression levels,
and oneCD161+CD4+T cell population expressing intermediate
levels of CD161 only (Takahashi et al., 2006; Kang et al., unpub-
lished observation), as shown in Figure 1. The functional relation-
ship between the two populations of CD161 positive CD8+T cells,
and the signiﬁcance of a CD161high population within CD8+ T
cells which is largely absent from the CD4+ population, is yet to
be fully deﬁned.
CD161 AS A MARKER IL-17 PRODUCING CELLS
The identity of theseCD161-expressingT subsets remained elusive
until CD161 was identiﬁed as being signiﬁcantly upregulated in T
helper (Th) 17 clones compared to those of Th1 and Th2 (Cosmi
et al., 2008). These CD4+ Th17 cells represent a novel helper
cell subset, which secrete both IL-17A and IL-17F and express the
master transcription factor retinoic acid-related orphan receptor
(ROR)γt (Ivanov et al., 2006). In peripheral blood, IL-17 secreting
CD4+ cells are contained within the CD161+ fraction and these
cells express RORγt. Hence, CD161 is considered a hallmark of
Th17 cells.
As a result of the correlation between IL-17 secretion and
CD161 amongst Th17 cells, Maggi et al. (2010) investigated
CD161 expression in other T cells capable of producing IL-17.
In addition to Th17 cells, IL-17 secreting CD8+ T cells have also
been isolated from the circulation of healthy individuals (Kondo
et al., 2009). Interestingly, in all T cell subsets, including these
CD8+ T cells, the ability to secrete IL-17 was virtually restricted
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FIGURE 1 | CD161-expressing populations in CD8+ and CD4+T cells. Flow cytometric analyses of T cells from healthy individuals demonstrate the
existence of three populations of CD8+T cells; CD161−, CD161int, and CD161high, and two CD4+T cell populations; CD161− and CD161int. Some donors may
display a CD161high CD4+ population, but in the majority CD161 positive CD4+T cells comprise a single population with intermediate expression levels.
to those cells expressing CD161. These CD161+ cells express
the Th17 transcription factor RORγt. Furthermore, Maggi et al.
(2010) demonstrated that naïve CD161−CD4+T cells transduced
with RORγt produced IL-17 and upregulated CD161 expression,
while inhibition of RORγt downregulated both IL-17 and CD161
expression in Th17 clones. Similarly, RORγt transduction in dif-
ferentiating CD8+ T cells induced high levels of IL-17 production
when these cells were cultured in the presence of Th17-polarizing
cytokines (Huber et al., 2009). Thus, the observed correlation
between IL-17 production and CD161 expression may result from
dual control of gene expression by the transcription factor RORγt,
which may be activated or upregulated under type 17-polarizing
conditions.
CD8+T cells capable of secreting IL-17 have been further char-
acterizedbyBillerbeck et al. (2010). This studydemonstrated IL-17
secretion amongst CD8+ T cells was restricted to those expressing
high levels of CD161. CD161highCD8+ cells display a phenotype
similar to Th17 cells, such as the upregulated expression of RORγt,
CCR6, and IL-18R, and as such have been described as Tc17 cells.
Although these cells express the CD8 co-receptor, Tc17 cells dis-
play reduced cytotoxic potential compared to conventional CD8+
effector T cells associated with a low expression of granzyme B
and perforin, and reduced cytotoxic degranulation as measured by
CD107a upregulation. Tc17 populations independently described
in mice also displayed limited cytolytic capability, with only a very
small fraction positive for granzymeB (Hamada et al., 2009;Huber
et al., 2009).
AREAS OF CONTROVERSY
However, several opposing theories have recently emerged regard-
ing the identity of CD8+ T cells expressing high levels of CD161,
summarized in Table 1. CD161, when co-expressed with IL-18Rα,
has also been suggested as a marker of a prototypical CD8+
population known as memory stem cells (Turtle et al., 2009),
which survive cytotoxic chemotherapy through the rapid efﬂux
of cytotoxic drugs. Like those cells described by Billerbeck et al.
(2010), these memory cells expressed low levels of granzyme B and
perforin, demonstrated reduced proliferation, and were CD28+
and CD27+. However, Dusseaux et al. (2011) suggest that in
healthy adults CD161highCD8+ T cells largely represent mucosal
associated invariant T (MAIT) cells; an innate-like T cell subset
which express the invariant TCRα chain Vα7.2 – Jα33 and are
restricted by MHC-related molecule 1 (MR1; Martin et al., 2009).
Approximately 10% of MAIT cells were found to express IL-17 in
response to PMA and ionomycin and these cells expressed RORγt.
MAIT cells have therefore also been suggested to represent Tc17
cells. However, while Tc17 cells can react to viral peptides (Biller-
beck et al., 2010),MAIT cells were unable to react to virus-infected
APCs (Le Bourhis et al., 2010). Further studies are consequently
required to clarify the degree of overlap between these putative
cell types. Current analysis of Tc17 cells indicates that although the
majority, likeMAIT cells, areVα7.2+, these cells do not completely
encompass the CD161high population (Walker et al., 2010).
CD161 AND MEMORY PHENOTYPE
Despite this disagreement regarding TCR usage, in all studies
CD161 expression is consistently associated with a memory phe-
notype within the adult circulation, being described in CD4+
(Takahashi et al., 2006; Annunziato et al., 2007; Cosmi et al., 2008;
Kleinschek et al., 2009), CD8+ (Takahashi et al., 2006; Maggi
et al., 2010), DN TCRαβ+, and TCRγδ+ T cells (Maggi et al.,
2010). Whereas approximately half of CD161intCD4+ T cells dis-
play a central memory phenotype, being CD62L+ CCR7+, less
than 1% of CD161highCD8+CD45RO+ cells expressed this phe-
notype, and are therefore classed as being effector memory cells
(Takahashi et al., 2006). This may suggest that CD161 expression
is acquired as a result of immune stimulation, and may itself be
a memory marker. However, CD161 negative cells do not alter
in CD161 expression with anti-CD2, -CD3 and -CD28 stimu-
lation, and inﬂuenza-speciﬁc cells did not express CD161 after
re-stimulation, even in the presence of cytokines (Northﬁeld et al.,
2008), implying that CD161 is not simply a marker of activation.
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Table 1 |Three parallel characterizations of CD161highCD8+T cells.
MAIT cells (Martin et al., 2009; Gold
et al., 2010; Dusseaux et al., 2011)
Tc17 cells (Northfield et al., 2008;
Billerbeck et al., 2010)
CD8 memory stem cells
(Turtle et al., 2009)
Surface phenotype Vα7.2+ CD161high IL-18Rα+ CD161high IL-18R+ CD161high IL-18Rα+Rh123-efﬂuxing
Frequency ∼1 in 10 mature CD8 or DNT cells 1 in 6 circulating CD8+T cells Low
Cord blood Present: CD45RA+CD161high IL-18Rα+ Present: CD45RA+ CD161high CCR6+ Absent
IL-17 production Yes Yes Unknown
RORγt Expressed Expressed Unknown
Tissue trophism High numbers in liver and intestine Enriched in liver during inﬂammation, enriched
in healthy tonsillar, and epithelial kidney tissue
None
Speciﬁcity Respond to bacterially infected APCs Some speciﬁcity for HCV demonstrated, but
not for other viruses, e.g., HIV, CMV, and
inﬂuenza
Respond to APCs pulsed with viral
peptides
This table illustrates both the similarities and differences between the main observations concerning the phenotype of CD161highCD8+T cells. Billerbeck et al. (2010)
characterize these cells asTc17 cells, reﬂecting their similarity toTh17 cells, whileTurtle et al. (2009) identiﬁed high expression of CD161 as a marker of CD8+ memory
stem cells. A recent study by Dusseaux et al. (2011), however, suggests that both these cell types represent the previously characterized MAIT cell population.
Furthermore, CD161 is expressed both by a subset of T cells
in the fetal liver and on a minor population of CD3+ thy-
mocytes (Lanier et al., 1994; Martin et al., 2009). This indi-
cates, therefore, that expression is induced early in ontogeny.
CD161intCD4+ (Cosmi et al., 2008) and CD161highCD8+ (Mar-
tin et al., 2009; Billerbeck et al., 2010) T cells have also been isolated
from umbilical cord blood (UCB), where they display a naïve
phenotype. When cultured in the presence of Th17-polarizing
cytokines, development of IL-17 production is restricted to the
CD161+CD4+CD45RA+ fraction (Cosmi et al., 2008), implying
that Th17 cells originate from a CD161+CD4+ T cell progenitor.
This suggests that thoseCD161+ cells identiﬁed in cord blood rep-
resent the precursors of memory CD161+ T cells found in adults.
What induces the maturation of these cells to display a memory
phenotype after birth is yet to be deﬁned.
CD161 AS AN EFFECTOR MOLECULE
It is clear that determining the function of CD161 would greatly
aid the functional phenotyping of those cells expressing this C-
type lectin. Crosslinking of CD161 by anti-CD161 antibodies has
previously had variable effects on both human NK and T cells.
Aldemir et al. (2005), observed that ligation of CD161 was not
sufﬁcient to trigger IFN-γ production by T cells, yet did enhance
secretion with the simultaneous engagement of CD3. Conversely,
Rosen et al. (2005, 2008) found that crosslinking of CD161 did not
affect cytokine production in CD4+ T cells, but reduced TNFα
production by CD8+ T cells in a proportion of donors tested.
CD161 LIGANDS
As the only human ortholog of the rodent NK receptor fam-
ily known as NKRP1, a central aim in determining the func-
tion of CD161 is the identiﬁcation of this receptor’s ligand(s).
Seven murine NKRP1 genes have thus far been identiﬁed, termed
Nkrp1a-g (with Nkrp1e thought to be a pseudogene; Plougastel
et al., 2001a), heterogeneously expressed by NK cells (Aust et al.,
2009). In C57BL/6 mice NKR-P1C carries the NK cell antigenic
marker NK1.1 (Glimcher et al., 1977; Koo and Peppard, 1984) and
also marks murine NK-T cells (MacDonald, 1995). This NKRP1
receptor may also be expressed during activation of CD8+ T
cells (Aust et al., 2009). Unlike classical NK cell receptors, NKRP1
receptors recognize non-MHC ligands of the C-type lectin related
(Clr) family, encoded by genes interspersedwithin theNkrp1 genes
themselves (Plougastel et al., 2001b; Iizuka et al., 2003). Yet, like
other NK cell receptors, Nkrp1 gene products can be classiﬁed as
either activating or inhibitory. NKRP1A, C and F contain charged
residues within their transmembrane domains, and are therefore
considered to be activating receptors, inducing NK cytolytic activ-
ity, while NKRP1B and NKRP1D lack charged transmembrane
residues and deliver inhibitory signals when crosslinked (Aust
et al., 2009). NKRP1B and D appear to be closely related inhibitory
molecules, expressed in BALB/c and C57BL/6 mice, respectively,
with the Nkrp1d gene of C57BL/6 mice suggested to represent a
divergent allele of the Nkrp1b gene of other strains (Carlyle et al.,
2006). Both NKRP1B and D bind the Clr-b protein osteoclast
inhibitory lectin (Ocil; Carlyle et al., 2004). The human ortholog
of this ligand, also known as lectin-like transcript 1 (LLT1), was
simultaneously identiﬁed by two groups as a ligand for CD161 in
humans (Aldemir et al., 2005; Rosen et al., 2005). This interaction,
conserved between mouse and man, may suggest that NKRP1B
and D represent the closest relations to human CD161. The sug-
gested ligands for murine NKRP1 receptors and human CD161
are shown in Figure 2.
In humans, LLT1 is thought to be expressed by both activated
APCs (Aldemir et al., 2005; Rosen et al., 2008) and lymphocytes
(Aldemir et al., 2005). Despite transcripts and proteins of CD161
being identical betweenNKandT cells, ligation by LLT1 appears to
induce opposing effects in these subsets, inhibiting or enhancing
IFNγproduction, respectively.A subsequentCD161 ligand, related
to LLT1, has also been recently identiﬁed, termed proliferation-
induced lymphocyte-associated receptor (PILAR; Huarte et al.,
2008). As its name implies, PILAR is expressed on lymphocytes
and expression is upregulated in T cells upon TCR stimulation. In
the absence of CD28 costimulation, PILAR increases the prolifera-
tion of naïve T cells, suggesting that CD161 acts as a costimulatory
receptor, enhancing proliferation through interactionwith PILAR.
Lately, however, the interaction between PILAR and CD161 has
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FIGURE 2 | NKRP1 ligands in mouse and man. Putative ligands for
CD161, expressed on humanT lymphocytes, are shown on the left side of
the ﬁgure.The CD161 ortholog in mice exists as a family of genes, known as
NKRP1 receptors, which are thought to consist of at least three activating
and two inhibitory receptors, as shown on the right. The ligands for these
receptors are Clr proteins, with the two known ligands depicted. A recent
study suggested that NKRP1F may also recognize Clr-x (Aust et al., 2009).
been disputed, and it has been suggested that the PILAR gene
encodes a ligand (termed keratinocyte-associated C-type lectin,
KACL) which interacts with a distinct receptor, a further C-type
lectin named NKp65 (Spreu et al., 2010).
CD161 AND TISSUE HOMING
CD161 has also been proposed to play a role in transendothelial
migration. CD161+ cells migrated across endothelial cell mono-
layers to a greater extent than CD161−CD4+ lymphocytes (Poggi
et al., 1997), and this was reduced by incubation with anti-CD161
monoclonal antibody. This may occur through binding of CD161
to acidic oligosaccharides on the endothelial cell surface, as has
been shown in NK cells (Bezouska et al., 1994). Interestingly,
migration occurred without chemotactic stimuli, which may be
indicative of a preference of these cells to home to speciﬁc tissues.
Indeed, both CD4+ and CD8+ CD161+ T cells make up more
than half of T cells in the healthy human intestine (O’Keeffe et al.,
2004) and CD161-expressing CD8+ T cells appear to home to the
liver (Ishihara et al., 1999).
CD161 EXPRESSION AND DISEASE
CD161+ T CELLS AND INFECTION
These cells are also selectively recruited during inﬂammation,with
CD4+ (Kang et al., unpublished observation) andCD8+CD161+
T cells enriched in the liver in response to both hepatic infec-
tion and non-alcoholic steatohepatitis (Billerbeck et al., 2010).
CD8+ T cells speciﬁc for HCV and hepatitis B (HBV), but not
HIV, cytomegalovirus (CMV), or inﬂuenza, express signiﬁcant
levels of CD161 (Northﬁeld et al., 2008) and these T cells display
responses against HCV-derived peptides (Billerbeck et al., 2010).
CD161intCD4+ T cells are also markedly enriched in the liver of
patients with HCV (Kang et al., unpublished observation) and
HCV-speciﬁc Th17 cells have been described (Rowan et al., 2008).
Expression of CD161, particularly on CD8+ T cells,may therefore
differentiate responses within speciﬁc organs such as the liver. Yet
the role of these cells in either disease control or immune-mediated
damage is largely unknown. Recently,Wang et al., correlated levels
of IL-17with degree of ﬁbrosis inHBV infection,with intrahepatic
IL-17 localized to ﬁbrotic regions (Wang et al., 2011). Conversely,
secretion of IL-22 by these cells may in fact be hepatoprotective
(Zenewicz et al., 2007; Kang et al., unpublished observation).
However, these cells are not limited to liver-speciﬁc responses.
Tc17 populations within mice protect against lethal inﬂuenza
infection (Hamada et al., 2009), an effect shown to be due, at
least partially, to their secretion of IL-17. CD161+ MAIT cells,
on the other hand, respond to bacterially infected cells, including
both APCs (Le Bourhis et al., 2010) and Mycobacterium tubercu-
losis-infected lung epithelial cells (Gold et al., 2010), suggesting
a role in detection and control of bacterial infections. MAIT
cells are thought to be unresponsive to virus-induced or virus-
derived ligands (Le Bourhis et al., 2010). Resolution of CD161-
expressing CD8+ T cell speciﬁcity, in addition to aiding classiﬁca-
tion,would also assist the identiﬁcation of their role within human
disease.
CD161+ T CELLS IN AUTOIMMUNE DISEASE
In contrast to the situation with host defense, much research has
concentrated on the role of CD161intCD4+ T cells in autoim-
mune disease, which was previously considered to be Th1-driven
(Cua et al., 2003). IL-17 knockout mice exhibit delayed onset,
reduced severity, and early recovery of experimental autoimmune
encephalomyelitis (EAE), the murine model of multiple sclero-
sis (MS). In humans, IL-17 levels are increased in patients with
MS (Lock et al., 2002) and IL-17+ T cells have been identi-
ﬁed within MS brain lesions (Tzartos et al., 2008). Patients with
MS also display a signiﬁcantly higher percentage of peripheral
blood CD161highCD8+ T cells than healthy individuals (Anni-
bali et al., 2011). More speciﬁcally, polymorphisms in CD161 have
recently been implicated in MS, suggesting a role for CD161 itself
in autoimmune pathogenesis (Haﬂer et al., 2007).
CD161-expressing T cells have also been implicated in other
autoimmune diseases.High proportions of CD161intCD4+T cells
were found in inﬂammatory inﬁltrates of patients with psori-
asis (Cosmi et al., 2008) and Crohn’s disease (CD; Kleinschek
et al., 2009). Indeed, CD161intCD4+ T cells demonstrated a 20-
fold increase in gut samples from patients with CD compared to
healthy controls and those isolated from the blood produced sig-
niﬁcantly more IL-17 on stimulation with PMA and ionomycin.
Tc17 cells are also signiﬁcantly enriched in inﬂammatory inﬁl-
trates from donors with psoriatic and rheumatoid arthritis (RA;
Billerbeck et al., 2010).However, the signiﬁcance of CD161 expres-
sion by both Th17 and Tc17 within the disease process has yet to
be determined.
CONCLUSION AND FUTURE WORK
CD161 expression is evident within all T cell subsets, and is asso-
ciated with cells expressing a memory phenotype in the adult
circulation. However, CD161 does not simply represent a marker
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of activation, memory, or exhaustion. Neither stimulation nor re-
stimulation induced expression in CD161− cells, and CD161+
cells express only low levels of the exhaustionmarkerPD-1 (North-
ﬁeld et al., 2008; Billerbeck et al., 2010). Furthermore, CD161
expression has been identiﬁed in naïve cells within UCB (Cosmi
et al., 2008; Billerbeck et al., 2010),withCD45RA+CD161+CD4+
T cells expressing high levels of mRNA for RORγt, IL-23R, and
CCR6. CCR6 is also expressed on CD161highCD8+ T cells iso-
lated from cord blood (Billerbeck et al., 2010). This suggests that
these CD161 positive cells, while apparently naïve, represent a
population precommitted to a distinct pathway of differentiation.
During ontogeny T cells develop within the thymus, where lin-
eage commitments such as CD4 vs. CD8 co-receptor expression
are made. These fate decisions inﬂuence the phenotype of these
cells upon their release into the periphery. Interestingly, single pos-
itive thymocytes from the post-natal thymuswhich express CD161
have also been identiﬁed (Lanier et al., 1994; Cosmi et al., 2008;
Martin et al., 2009). This, together with early expression of RORγt
and characteristic cytokine receptors in UCB CD161+ lympho-
cytes, suggests that expression of CD161 may indicate an early
lineage commitment made by cells during development. Indeed,
this decision may even be made prior to division into CD4 or
CD8 subtype, with the possible pathways by which CD161+ cells
develop illustrated in Figure 3. It appears that these CD161+ thy-
mocytes represent the precursors of those memory Th17 and Tc17
cells identiﬁed within the adult circulation. Expression of CD161
early in ontogeny could also explain the identiﬁcation by Turtle
FIGURE 3 | Expression of CD161 early during the development ofT
cells within the thymus.This ﬁgure illustrates two possible pathways by
which CD161 expression may be determined during development; either
before co-receptor expression is decided (A) or at the single positive stage,
whenT cells are either CD4+ or CD8+ (B). Th17 cells only develop from
CD161+ CD4+ cells, however these cells can also develop into Th1 or Th2
cells. DN, double negative; DP, double positive.
et al. (2009) of CD161highCD8+ T cells with stem cell-like prop-
erties. Expression of CD161 during development suggests that
these cells may become precommitted to display characteristics of
a “CD161 positive” phenotype, possessing shared characteristics
independent of helper/cytotoxic lineage, such as IL-17 secretion.
As such, this phenotypic commitmentmay be decided prior to fur-
ther lineage development, as suggested in Figure 3A. Programmed
chemokine receptor expression in CD161+ naïve cells, such as
CCR6, may also indicate the ability of these cells to preferentially
home to speciﬁc tissues, where they are found in elevated numbers
(Huarte et al., 2008; Spreu et al., 2010). Evidently the development
of CD161-expressing cells is still largely unexplored.However, clar-
iﬁcation of the signiﬁcance of CD161 expression during ontogeny
may provide clues regarding the function of this unique cell type.
As CD161 marks T cells with the ability to secrete IL-17
(Maggi et al., 2010), expression of CD161 during development
would appear to commit cells to a type 17 pathway of differenti-
ation. However, CD161 expression was also identiﬁed on IFNγ+
and IFN-γ/IL-17 co-secreting CD8+ (Billerbeck et al., 2010) and
CD4+ T cells (Cosmi et al., 2008). CD4+IL-17+IFNγ+ cells have
been termed Th17-1 (Jadidi-Niaragh and Mirshaﬁey, 2011) and
express the chemokine receptors CCR6 and CXCR3, distinguish-
ing them from Th17 cells which express CCR6 and CCR4 (Acosta-
Rodriguez et al., 2007). However, whether these cells represent a
stable subset or a transitional phenotype (El-behi et al., 2010) is yet
to be resolved, with the latter case suggesting plasticity within the
Th17 phenotype. Indeed, human Th17 clones have been shown
to demonstrate a degree of plasticity when stimulated in the pres-
ence of IL-12, downregulating RORγt while upregulating the Th1
transcription factor T-bet,with these cells subsequently producing
IFN-γ in addition to IL-17 (Annunziato et al., 2007). Therefore,
while CD161 is agreed to mark Th17 cells, and descriptions of
these cells are extensive, the dual functionality demonstrated by
some also reveals the difﬁculty in exclusively categorizing T cells
into distinct subsets.
It is clear that much is left to be determined regarding the sig-
niﬁcance of CD161 expression, and further of different levels of
expression, by this subset of human T cells. Studies to identify this
receptor’s ligands, and more importantly the effect of ligand bind-
ing on T cell function, will provide clues regarding the purpose of
CD161 expression. In addition, characterization of both the phe-
notype and function of these subsets is fundamental to enabling
their role within human diseases to be determined. The sugges-
tion that CD161 supports activation-induced expansion of T cells
(Huarte et al., 2008), and the implication of CD161 polymor-
phisms within MS (Haﬂer et al., 2007) could identify CD161, or
indeed other receptors onCD161+T cells, as potential therapeutic
targets in the treatment of a wide range of diseases.
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